Abstract Details

Title Effects of Guideline on Prevalence of Cerebral Sinus Venous Thrombosis (CSVT) before and after 2011: Call to Action

Topic Practice, Policy, and Ethics

Presentation(s) P4 - Poster Session 4 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-078

Objective

Our study objectives were to assess trends of CSVT prevalence, LOS, Cost and mortality rate before and after published CSVT guidelines by American Stroke Association (ASA) in 2011.

Background CSVT is a relatively uncommon and potentially reversible condition with prompt diagnosis and multidisciplinary care.

Design/Methods We identified CSVT using ICD 9 CM code 325.0, 437.6, and 671.5 from NIS sample from 2005 to 2015. Joint point regression models were used to quantify Annual Percent Change (APC) to evaluate trends rate over time developed by US National cancer institute. Tests of significance use a Monte Carlo permutation method.

Results We identified total weighted CSVT 18,218 admission between 2005 to 2015. Prevalence of CSVT continued to be same with average APC 0.04% (CI -2.5% to 2.6%; P value >0.05; Joinpoint year 2012) in the period of 2005-2012, while after 2012 the prevalence continued to be increase with APC 18.72% (CI 8.0% to 30.5%; P value <0.05) in the period of 2012-2015. Inpatient cost continued to increase from 2005-2010 with APC 5.09% (CI -1.5% to 12.1%; P value>0.05; 2010) while after 2010, there was a downtrend with APC -1.40% (CI -7.6% to 5.2%; P value >0.05). The trend of LOS remained the same from 2005-2010 with APC -0.05% (CI -6.2% to 6.5%; P value>0.05; 2010) while after 2010, there was a downtrend with -3.87% (CI -9.8% to 2.4%; p >0.05). Trend of mortality was downtrend from 2005 to 2013 with APC -15.11% (CI -26.8% to -1.6%; P value <0.05; 2013). However, there was an uptrend after 2013 with APC 25.49% (CI -67.7% to 387.0%, P value >0.05).

Conclusions Trends of LOS and cost were decreasing after 2010 suggesting effectiveness of guidelines. There was increasing prevalence of CSVT from 2012 suggesting improving diagnostic accuracy and advances of neuroimaging. Further mortality trend is needed after 2013 for better assessment.

Authors/Disclosures
Smit D. Patel, MD, MPH PRESENTER	Dr. Patel has nothing to disclose.
	No disclosure on file
Neeta Garg, MD (Harbor UCLA Medical Center)	Dr. Garg has nothing to disclose.
Gracia C. Mui, MD (UConn Health)	Dr. Mui has nothing to disclose.

��ɫ��

��ɫ��